Inovio Pharmaceuticals, Inc. (INO) Receives Average Rating of “Hold” from Brokerages
Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have earned an average recommendation of “Hold” from the thirteen analysts that are currently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $20.20.
INO has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 target price on shares of Inovio Pharmaceuticals in a research report on Tuesday, September 12th. BidaskClub raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, September 9th. ValuEngine downgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 9th. Maxim Group set a $12.00 target price on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Finally, Royal Bank Of Canada began coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, October 18th. They issued an “outperform” rating and a $11.00 target price on the stock.
Inovio Pharmaceuticals (NASDAQ:INO) opened at $4.38 on Thursday. Inovio Pharmaceuticals has a 1 year low of $4.20 and a 1 year high of $9.86.
A number of hedge funds have recently made changes to their positions in INO. Belpointe Asset Management LLC bought a new position in Inovio Pharmaceuticals during the 3rd quarter valued at about $150,000. Neuberger Berman Group LLC bought a new position in Inovio Pharmaceuticals during the 3rd quarter valued at about $115,000. Alyeska Investment Group L.P. bought a new position in Inovio Pharmaceuticals during the 3rd quarter valued at about $892,000. Allianz Asset Management GmbH lifted its stake in Inovio Pharmaceuticals by 12.4% during the 3rd quarter. Allianz Asset Management GmbH now owns 222,768 shares of the biopharmaceutical company’s stock valued at $1,412,000 after acquiring an additional 24,652 shares during the period. Finally, Engineers Gate Manager LP bought a new position in Inovio Pharmaceuticals during the 3rd quarter valued at about $117,000. 32.27% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Inovio Pharmaceuticals, Inc. (INO) Receives Average Rating of “Hold” from Brokerages” was published by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/12/07/inovio-pharmaceuticals-inc-ino-receives-average-rating-of-hold-from-brokerages.html.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.